Twist Bioscience (NASDAQ:TWST) Price Target Raised to $54.00

Twist Bioscience (NASDAQ:TWST) had its price objective boosted by Robert W. Baird from $48.00 to $54.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

TWST has been the subject of several other reports. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Barclays decreased their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Finally, Scotiabank raised their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Trading Up 0.1 %

NASDAQ TWST opened at $53.70 on Tuesday. The firm has a market capitalization of $3.19 billion, a P/E ratio of -14.92 and a beta of 1.87. The business has a fifty day simple moving average of $48.84 and a 200 day simple moving average of $46.32. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) EPS. As a group, sell-side analysts predict that Twist Bioscience will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 7,968 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $382,464.00. Following the completion of the transaction, the chief executive officer now owns 581,584 shares of the company’s stock, valued at approximately $27,916,032. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,002 shares of company stock valued at $2,851,681. 3.01% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans bought a new position in Twist Bioscience in the 3rd quarter worth about $43,992,000. State Street Corp boosted its stake in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Wellington Management Group LLP boosted its stake in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Jennison Associates LLC boosted its position in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after acquiring an additional 302,884 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after acquiring an additional 237,772 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.